Correction to “A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL)”

Visram A, Hayman SR, Dispenzieri A, et al. Am J Hematol. 2023;98(8):1277-1285. doi: 10.1002/ajh.26990.

In this article, we forgot to acknowledge that the work was supported by the Paul Calabresi K12 Career Development Award (CA90628-21).

We apologize for this error.